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ABSTRACT
Objectives Anticarbamylated protein (anti-CarP)
antibodies are a novel family of autoantibodies recently
identiﬁed in patients with inﬂammatory arthritis. The aim
of this study was to investigate their association with
long-term outcomes of disability and disease activity over
20 years’ follow-up in a cohort of patients with
inﬂammatory polyarthritis (IP).
Methods Norfolk Arthritis Register recruited adults
with recent-onset swelling of ≥2 joints for ≥4 weeks
from 1990 to 2009. At baseline, Health Assessment
Questionnaire (HAQ) and 28 joint disease activity scores
(DAS28) were obtained, and C reactive protein,
rheumatoid factor (RF), anticitrullinated protein
antibodies (ACPA) and anti-CarP antibodies were
measured. Further HAQ scores and DAS28 were
obtained at regular intervals over 20 years. Generalised
estimating equations were used to test the association
between anti-CarP antibody status and longitudinal HAQ
and DAS28 scores; adjusting for age, gender, smoking
status, year of inclusion and ACPA status. Analyses were
repeated in subgroups stratiﬁed by ACPA status. The
relative association of RF, ACPA and anti-CarP antibodies
with HAQ and DAS28 scores was investigated using a
random effects model.
Results 1995 patients were included; 1310 (66%)
were female. Anti-CarP antibodies were signiﬁcantly
associated with more disability and higher disease
activity, HAQ multivariate β-coefﬁcient (95% CI) 0.12
(0.02 to 0.21), and these associations remained
signiﬁcant in the ACPA-negative subgroups. The
associations of RF, ACPA and anti-CarP antibodies were
found to be additive in the random effects model.
Conclusions Anti-CarP antibodies are associated with
increased disability and higher disease activity in patients
with IP. Our results suggest that measurement of anti-
CarP antibodies may be useful in identifying ACPA-
negative patients with worse long-term outcomes.
Further, anti-CarP antibody status provided additional
information about RF and ACPA.
BACKGROUND
Rheumatoid arthritis (RA) is a heterogeneous
inﬂammatory arthritis, and individual patient out-
comes can vary from mild to disabling and life lim-
iting.1 2 The presence or absence of autoantibodies
provides important prognostic information to clini-
cians and patients. Rheumatoid factor (RF) and, in
particular, anticitrullinated protein antibodies
(ACPA) have been associated with more severe
disease activity,3 4 greater levels of disability5 and
increased mortality.6 They also form part of the
2010 American College of Rheumatology (ACR)/
European League Against Rheumatism (EULAR)
classiﬁcation criteria for RA.7 These criteria were
developed with the aim of identifying patients with
RA early in the natural history of the disease, using
the initiation of disease-modifying antirheumatic
drugs as their gold standard. Patients who lack
ACPA and RF have been shown to be less likely to
fulﬁl the 2010 RA criteria, although they may fulﬁl
the older 1987 criteria.8 9 Nevertheless, in clinical
practice, there remains a subset of apparently sero-
negative patients who go on to experience high
levels of disease activity and disability. If these
patients could be distinguished from those patients
with a milder disease course, they could beneﬁt
from early aggressive intervention.
Recently, a new group of autoantibodies, anticar-
bamylated protein (anti-CarP) antibodies, has been
identiﬁed in the sera of patients with RA.10 These
antibodies are directed against a post-translational
modiﬁcation of the amino acid lysine to homoci-
trulline in the presence of cyanate.11 They have
been shown to predate the onset of symptoms,12–14
and may occur before or after the development of
ACPA.12 Further, they have been shown to predict
development of arthritis in patients with arthral-
gia.15 However, it is not yet known if they are asso-
ciated with long-term disability and disease activity.
In addition, it would be clinically relevant to under-
stand the inﬂuence of anti-CarP antibody status in
patients with and without the other autoantibodies
(RF and ACPA), as well as how much prognostic
information is contributed by each antibody.
As patients with anti-CarP antibodies may lack
RF or ACPA, and therefore, be less likely to fulﬁl
RA criteria, it is important to study a broad group
of patients presenting with inﬂammatory polyar-
thritis (IP), which would include a subgroup that
meet RA criteria. The aims of this study were (a) to
describe the prevalence and co-occurrence of RF,
ACPA and anti-CarP antibodies in patients with IP,
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(b) to investigate the relationship between anti-CarP antibody
status and both disability and disease activity measured over
time in patients presenting with IP, (c) to investigate these rela-
tionships in ACPA-positive and ACPA-negative subgroups and
(d) to describe the additional predictive information provided
by measuring these antibodies.
METHODS
Patients and follow-up
Patients were included from the Norfolk Arthritis Register
(NOAR). This cohort has been described previously16 Brieﬂy,
adults >16 years old with at least two swollen joints for at least
4 weeks in the former Norfolk Health Authority area were
recruited between 1990 and 2009. Patients recruited from 1995
to 1999 were excluded from this study as they were not fol-
lowed beyond 2 years. Patients were also excluded if no serum
sample obtained within the ﬁrst year after recruitment was avail-
able. The selection of patients for the analysis is shown in full in
the online supplementary data ﬁle. At baseline, in NOAR,
patients are assessed by a nurse who obtains demographic
details, medication details and smoking history, and performs a
51 tender and swollen joint count. The patients complete the
British version of the Health Assessment Questionnaire
(HAQ).17 Patients in NOAR are followed up yearly for the ﬁrst
3 years and then at 5, 7, 10, 15 and 20 years from baseline.
Patients repeat the HAQ and the nurse assessment at each
follow-up. Blood samples are taken at baseline and every 5 years
thereafter, stored frozen and subsequently tested for RF (latex
test), ACPA (Axis-Shield Diastat Anti-CCP kit) and C reactive
protein (CRP) in Manchester, UK. The cut-offs for a positive
test were set according to the manufacturers’ guidelines at
>40 iu/L for RF, >5 iu/L for ACPA and >5 mg/L for CRP. The
three-item disease activity score (DAS28-CRP)18 is calculated at
baseline and every 5 years, and the 2010 ACR/EULAR criteria
are applied retrospectively using baseline data. In 2013–2014,
stored sera were sent to Leiden University Medical Center, The
Netherlands, in a blinded fashion for measurement of anti-CarP
antibodies using an in-house ELISA based on carbamylated fetal
calf serum (FCS) as described before.10 Brieﬂy, non-modiﬁed
FCS and modiﬁed-FCS were coated on Nunc MaxiSorp plates
(Thermo Scientiﬁc) overnight. After washing and blocking, the
wells were incubated with serum. Bound human IgG was
detected using rabbit antihuman IgG antibodies (Dako) and
then horseradish peroxidase (HRP)-labelled goat antirabbit IgG
antibody (Dako). Following ﬁnal washings, HRP enzyme activity
was visualised using 2,2'-azino-bis(3-ethylbenzothiazoline-6-sul-
phonic acid)10 NOAR is approved by the Norwich Local
Research Ethics Committee, and all patients gave written
consent.
Statistical analysis
Differences in baseline disability (measured by the HAQ) and
disease activity (measured by 28 joint disease activity score
(DAS28)) between anti-CarP antibody positive and negative
patients were evaluated using the Kruskal–Wallis test.
Generalised estimating equations (GEE) were used to assess the
association between anti-CarP antibody status and HAQ and
DAS28 measured over time, allowing for the inclusion of
patients with incomplete follow-up data. A time-interaction
term was included to investigate any potential change in the
relationship between baseline anti-CarP antibody status and
HAQ or DAS28 scores. Univariate and subsequently multivari-
ate models were constructed, adjusting for age, gender, smoking
status (stratiﬁed as current, previous or never smoked),
polynomials of disease duration (to better ﬁt the outcome mea-
sures), year of recruitment to NOAR and ACPA status. The ana-
lyses were repeated in the ACPA-positive and ACPA-negative
subgroups and in patients who did and did not meet the 2010
RA classiﬁcation criteria at baseline, omitting the ACPA con-
founder variable. In addition, as DAS28 was only available
every 5 years, sensitivity analyses were performed using the total
swollen joint count as an alternative measure of disease activity
over time.
The individual effects of RF, ACPA and anti-CarP antibodies
were then investigated. For each of the two outcomes of inter-
est, a random effects model was used to test the association with
each antibody. A three-way interaction term was included to
investigate potential interactions between the antibodies; the
resulting β-coefﬁcient for each antibody estimated the added
effect of that antibody. The ﬁnal model was also adjusted for
age, gender, smoking status, disease duration and year of
recruitment.
A proportion of patients had anti-CarP antibodies tested, but
had missing data on some of the baseline covariates in the
model (ACPA, CRP and smoking status; see table 1). To account
for this, missing data were imputed using multiple imputation
with chained equations, and a sensitivity analysis was performed
in the imputed dataset. All analyses were performed using
STATA V.12 software package (Stata, College Station, Texas,
USA).
RESULTS
A total of 1995 patients with IP were included; 1310 (66%)
were female, and median age at onset (IQR) was 55 (43–66)
years. Four hundred and sixty (23%) patients were anti-CarP
antibody positive, and 1221 (61%) fulﬁlled the 2010 ACR/
EULAR classiﬁcation criteria for RA at baseline. The median
follow-up time (IQR) was 8 (5–12) years. A summary of the
baseline characteristics is shown in table 1. Baseline character-
istics of patients who fulﬁlled the 2010 RA criteria are shown in
online supplementary table S1. A total of 1476 patients were
tested for all three antibodies; of whom, 297 (20%) were
anti-CarP antibody positive and 74 (5%) tested positive for only
anti-CarP antibodies. The distribution of all antibody statuses is
shown in ﬁgure 1.
Levels of disability at baseline differed between anti-CarP
antibody positive and negative patients, respective median HAQ
(IQR) 1.125 (0.5–1.75) and 0.875 (0.25–1.5), p<0.001. There
were also differences in baseline DAS28 scores, respective
median DAS28 (IQR) in the anti-CarP antibody positive and
negative groups were 4.23 (3.19–5.31) and 3.73 (2.80–4.63),
p<0.001.
In the GEE model, patients who were anti-CarP antibody
positive were, on average, more disabled at baseline, and
remained more disabled throughout follow-up compared with
those who were negative (ﬁgure 2), unadjusted GEE
β-coefﬁcient (95% CI) 0.21 (0.14 to 0.29), and this remained
signiﬁcant in the multivariate analysis, including adjustment for
ACPA status (table 2). Similarly, when DAS28 was the outcome
of interest, anti-CarP antibody positive patients had, on average,
higher levels of disease activity over time, unadjusted GEE
β-coefﬁcient 0.38 (0.25 to 0.50) (see online supplementary
ﬁgure S2). This association persisted in the multivariate model.
In the ACPA-negative subgroup, there was also a signiﬁcant asso-
ciation between anti-CarP antibody positivity and HAQ. It
should be noted that for both HAQ and DAS28, the multivari-
ate β-coefﬁcient (95% CI) were very similar between the
ACPA-negative and ACPA-positive groups, and these estimates
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were not signiﬁcantly different from each other. The interaction
with time covariate was not statistically signiﬁcant, meaning that
the difference in HAQ scores between the average anti-CarP
antibody positive patient and the average anti-CarP antibody
negative patient did not increase or decrease over follow-up;
this is displayed in ﬁgure 2. A time-interaction term was, there-
fore, not included in the ﬁnal models.
In patients who fulﬁlled the 2010 RA criteria at baseline,
anti-CarP antibody status was associated with DAS28, and there
was a trend to statistical signiﬁcance with HAQ, respective
multivariate β-coefﬁcients (95% CI) 0.18 (0.04 to 0.32) and
0.07 (−0.01 to 0.16) (see online supplementary table S2).
Interestingly, there was a signiﬁcant association with the HAQ
among the group of patients who did not fulﬁl the 2010 RA cri-
teria multivariate β-coefﬁcient (95% CI) 0.19 (0.06 to 0.33).
The sensitivity analysis with imputed missing covariates pro-
duced similar results (see online supplementary table S3), as did
the sensitivity analysis with the swollen joint count as the
outcome of interest (see online supplementary table S4).
In the model that assessed the relative contributions of ACPA,
RF and anti-CarP antibodies to long-term disability, no inter-
action was found between the antibodies, and the R-squared
value of the models were very similar with and without the
interaction term. Therefore, the effect of each antibody could
be considered to be additive rather than multiplicative. Both
ACPA and anti-CarP antibodies were signiﬁcantly associated
with long-term disability, as measured by the HAQ, and had
similar effect sizes, respective adjusted β-coefﬁcient (95% CI)
0.12 (0.02 to 0.21) and 0.13 (0.03 to 0.21) (table 3). However,
in the adjusted model, RF was not. In terms of disease activity
over time, again, ACPA and anti-CarP antibodies were signiﬁ-
cantly associated with DAS28 score over time, and RF was not
(table 3).
DISCUSSION
This is the ﬁrst study to investigate the associations between
anti-CarP antibody status and long-term disease activity and dis-
ability in patients with IP. We have shown that patients with
anti-CarP antibodies are more disabled, and have higher disease
activity early in the disease and continue to have more func-
tional disability and disease activity compared with anti-CarP
antibody negative patients. We have also shown that the inﬂu-
ence of anti-CarP antibody positivity is similar to that of ACPA
Figure 1 Distribution of antibodies in patients with IP who had all
three antibodies tested. ACPA, anticitrullinated protein antibodies;
anti-CarP, anticarbamylated protein; IP, inﬂammatory polyarthritis; RF,
rheumatoid factor.
Figure 2 HAQ scores over time by anti-CarP antibody status
(modelled by univariate GEE). Anti-CarP, anticarbamylated protein;
GEE, generalised estimating equations; HAQ, Health Assessment
Questionnaire.
Table 1 Baseline demographic and disease characteristics
Total cohort, n=1995
Patients with all
antibodies tested, n=1476
Missing,
n (% total cohort)
Female, n (%) 1310 (66) 983 (67) 0
Age at symptom onset (years), median (IQR) 55 (43–66) 54 (42–65) 0
Smoking status, n (%)
Never 706/1982 (36) 535 (36) 13 (1%)
Previous 793/1982 (40) 585 (40)
Current 483/1982 (24) 350 (24)
Disease duration (weeks), median (IQR) 33 (17–69) 34 (17–70) 0
HAQ, median (IQR) 0.875 (0.375–1.5) 0.75 (0.25–1.5) 23 (1%)
DAS28, median (IQR) 3.81 (2.88–4.82) 3.79 (2.85–4.78) 362 (18%)
RF positive, n (%) 658/1895 (35) 463 (31) 100 (5%)
ACPA positive, n (%) 389/1487 (26) 385 (26) 508 (25%)
Anti-CarP antibody positive, n (%) 460 (23) 297 (20) 0
CRP (mg/L), median (IQR) 8.7 (2–19) 8 (2–18) 362 (18%)
Satisfy 2010 RA classification criteria* n (%) 1221 (61) 893 (61) 0
On DMARDs at baseline assessment n (%) 722 (36) 501 (34) 0
*At baseline.
ACPA, anticitrullinated protein antibodies; anti-CarP, anticarbamylated protein; CRP, C reactive protein; DAS28, 28 joint disease activity score; DMARDs, disease-modifying antirheumatic
drugs; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor.
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when considering these outcomes and that measurement of the
different autoantibodies provides additional information.
The majority of anti-CarP antibody positive patients in our
study also demonstrated the presence of another antibody;
however, there was a subset of patients who were only positive
for anti-CarP antibodies. Of particular interest are the associa-
tions with poor outcomes in the ACPA-negative subgroup and
the model adjusting for ACPA status. In general, ACPA-negative
patients are considered to have a good prognosis.3 However,
there is a small group who do poorly. For example, in studies of
early arthritis cohorts, most patients who only fulﬁl the 1987
classiﬁcation criteria for RA (characterised by the hallmarks of
established RA such as radiological damage and nodulosis), and
not the 2010 criteria (characterised by raised inﬂammatory
markers and swollen/tender joint counts), are negative for RF
and ACPA.8 9 19 Knowledge of anti-CarP antibody status in
these patients, therefore, may be especially useful. In line with
our results, other cohorts have demonstrated an association
between anti-CarP antibody positivity and greater radiographic
damage in patients with inﬂammatory arthritis, and the sub-
group of these who are ACPA negative.10 14 In our study, as well
as stratifying patients with IP into ACPA-positive and
ACPA-negative subgroups, we also adjusted for ACPA in the ana-
lyses of the whole cohort. This is because a number of studies
have demonstrated that multiple autoantibodies can be
accumulated in the preclinical phase of RA,20 21 possibly via the
mechanism of epitope spreading, and ACPA usually appears
before RF.22 It, therefore, seemed reasonable to consider base-
line ACPA status a potential confounder.
In this study, we have addressed, for the ﬁrst time, the ‘added
value’ of testing for anti-CarP antibodies. Recent studies in the
literature have investigated the inﬂuence of the number of auto-
antibodies on disease outcomes.6 23 Therefore, in addition to
investigating the independent association of anti-CarP antibodies
with disease outcomes, we wanted to address whether additional
information is gained when RF and ACPA status is already
known. It was interesting to note in this analysis that the coefﬁ-
cients for ACPA and anti-CarP antibodies were very similar. This
suggests that, in terms of disability and disease activity over
time, the impact of ACPA and anti-CarP antibodies are similar
in patients with IP who test positive for these antibodies. Given
that our results demonstrated an additive effect of each anti-
body, it may, therefore, be useful to test more than one antibody
in clinical practice when trying to assess current and future dis-
ability and disease activity.
There are some limitations in our study. There are currently
no commercial assays available to test for anti-CarP antibodies,
which could restrict the clinical impact of these results.
However, the assay based on the methods described by Shi
et al10 has begun to be used more widely; to date, it has been
employed by two independent groups.24 25 In addition, a
number of companies are developing routine assays to measure
anti-CarP antibodies, which should become available in the near
future.
It is important to acknowledge that the effect sizes demon-
strated in this study do not meet some previously published
‘minimum clinically important difference’ (MCID) for the
HAQ.26 However, these MCIDs were calculated and validated
for use in clinical trials to test the effect of a speciﬁc treatment
over a set period of time. Others have argued that the MCID
estimates may be as low as 0.09 in observational studies.27 Our
results certainly exceed this threshold. As mentioned above, the
association of ACPA status with both HAQ and DAS28 demon-
strated similar effect sizes to anti-CarP antibody status.
A larger proportion of patients recruited into NOAR were
negative for all autoantibodies tested. This reﬂects the fact that
patients with IP are a broad group, which includes a subset of
patients with RA, and that the majority of patients are present-
ing early in their disease course. We have previously shown in
this cohort that 75%–95% of patients recruited go on to satisfy
the 1987 RA criteria.28 However, it is also important to note
that the 2010 RA criteria do not identify all patients with
Table 2 Association between anti-CarP antibody positivity and HAQ and DAS28
Total cohort
β (95% CI)
ACPA +ve
β (95% CI)
ACPA −ve
β (95% CI)
HAQ
Univariate 0.21 (0.14 to 0.29)** 0.10 (−0.04 to 0.24) 0.18 (0.04 to 0.32)*
Multivariate† 0.12 (0.02 to 0.21)* 0.09 (−0.05 to 0.23) 0.14 (0.01 to 0.27)*
DAS28
Univariate 0.38 (0.26 to 0.50)** 0.23 (0.01 to 0.46)* 0.11 (−0.11 to 0.34)
Multivariate*† 0.23 (0.07 to 0.39)* 0.25 (0.03 to 0.48)* 0.18 (−0.03 to 0.40)
*p<0.05.
**p<0.001.
†Adjusted for age, gender, smoking status, polynomials of disease duration and year of recruitment.
+ve, positive, −ve, negative; ACPA, anticitrullinated protein antibodies; anti-CarP, anticarbamylated protein; DAS28, 28 joint disease activity score; HAQ, Health Assessment
Questionnaire.
Table 3 Association between all autoantibodies and HAQ and
DAS28
Univariate
β (95% CI)
Multivariate†
β (95% CI)
HAQ
ACPA 0.20 (0.12 to 0.28)** 0.12 (0.02 to 0.21)*
RF 0.12 (0.05 to 0.18)** −0.03 (−0.12 to 0.05)
Anti-CarP antibodies 0.21 (0.14 to 0.29)** 0.13 (0.03 to 0.21)*
DAS28
ACPA 0.36 (0.23 to 0.50)** 0.26 (0.09 to 0.43)**
RF 0.28 (0.17 to 0.39)** −0.01 (−0.17 to 0.15)
Anti-CarP antibodies 0.38 (0.26 to 0.50)** 0.25 (0.09 to 0.42)**
*p<0.05.
**p<0.01.
†Adjusted for age, gender, smoking status, polynomials of disease duration and year of
recruitment.
ACPA, anticitrullinated protein antibodies; anti-CarP, anticarbamylated protein; DAS28,
28 joint disease activity score; HAQ, Health Assessment Questionnaire; RF, rheumatoid
factor.
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inﬂammatory arthritis who subsequently have poor outcomes,
and this is particularly seen in seronegative patients.29 It was
interesting, therefore, that anti-CarP antibody positivity was
associated with signiﬁcantly higher HAQ scores in the subgroup
of patients who did not satisfy the 2010 criteria at baseline. In
these patients, anti-CarP antibodies may be a marker of those
who will go on to develop RA.
We have not taken into account treatment in our analysis.
However, we did include the year of registration in the multi-
variate models, which would account for changes in prescrib-
ing patterns since 1990. Importantly, anti-CarP antibodies and
ACPA were tested on stored sera; therefore, the results were
not known to the treating clinicians, and could not have inﬂu-
enced treatment decisions. ACPA status may have been avail-
able through testing in routine clinical practice; however, this
would only apply to a small sample of NOAR patients seen
by rheumatologists since 2009 when the test became widely
available in Norfolk. In addition, as the anti-CarP antibody
ELISA is a relatively new test, it is not yet clear whether pro-
longed storage of sera before testing may inﬂuence the
results; adjustment for year of registration to NOAR will have
taken some of this effect into account. The anti-CarP anti-
body positive patients had more active disease and more dis-
ability at baseline, and thus, may have had more intensive
therapy, potentially introducing channelling bias. However, by
not including the impact of treatment, we have biased our
results towards the null hypothesis, and they are, therefore,
likely to be an underestimate in terms of statistical signiﬁ-
cance. A further limitation is that we were not able to test the
association between anti-CarP antibody status and radiological
damage over time; this is due to the fact that not all patients
in NOAR have radiographs, and, in those that do, they are
taken at different follow-ups, depending on when the patient
was recruited into the cohort. As a result, it would not be
possible to describe the relationship over time in the same
way as we have for disability and disease activity. Finally,
there were some missing data on covariates in this study; mul-
tiple imputation with chained equations was used to allow
inclusion of the whole sample in a sensitivity analysis, which
gave similar results to the main ﬁndings.
This analysis has shown that anti-CarP antibodies may be an
important additional family of antibodies in predicting long-
term outcomes in patients with IP, and may be useful to test in
addition to ACPA and RF.
Acknowledgements The authors gratefully acknowledge the support of clinical
staff in Norfolk, the NOAR research nurses and the NOAR patients.
Contributors JHH: study conception, analysis and interpretation of data, drafting
of manuscript, ﬁnal approval and agreement to accountability. MKV, REMT and LAT:
acquisition and analysis of data, revising manuscript, ﬁnal approval and agreement
to accountability. AB, DPMS and SMMV: study conception, revising manuscript, ﬁnal
approval and agreement to accountability. AJMG: acquisition of data, revising
manuscript, ﬁnal approval and agreement to accountability. ML: analysis and
interpretation of data, revising manuscript, ﬁnal approval and agreement to
accountability.:
Funding This collaboration was supported by IMI JU funded project Be The Cure,
contract no. 115142-2, and the NIHR Manchester Musculoskeletal Biomedical
Research Unit. NOAR is funded by Arthritis Research UK grant reference numbers
20380 and 20385. JHH is funded by Arthritis Research UK grant reference number
19743.
Competing interests None declared.
Ethics approval Norwich Local Research Ethics Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/
REFERENCES
1 van der Helm-van Mil AH, Breedveld FC, Huizinga TW. Aspects of early arthritis.
Deﬁnition of disease states in early arthritis: remission versus minimal disease
activity. Arthritis Res Ther 2006;8:216.
2 Humphreys JH, Warner A, Chipping J, et al. Mortality trends in patients with early
rheumatoid arthritis over 20 years: results from the Norfolk Arthritis Register.
Arthritis Care Res (Hoboken) 2014;66:1296–301.
3 Quinn MA, Gough AK, Green MJ, et al. Anti-CCP antibodies measured at disease
onset help identify seronegative rheumatoid arthritis and predict radiological and
functional outcome. Rheumatology (Oxford) 2006;45:478–80.
4 De RL, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein
antibodies in rheumatoid arthritis: diagnostic value, associations with radiological
progression rate, and extra-articular manifestations. Ann Rheum Dis
2004;63:1587–93.
5 Shidara K, Inoue E, Hoshi D, et al. Anti-cyclic citrullinated peptide antibody
predicts functional disability in patients with rheumatoid arthritis in a
large prospective observational cohort in Japan. Rheumatol Int 2012;32:
361–6.
6 Humphreys JH, van Nies J, Chipping J, et al. Rheumatoid factor and
anti-citrullinated protein antibody positivity, but not level, are associated with
increased mortality in patients with rheumatoid arthritis: results from two large
independent cohorts. Arthritis Res Ther 2014;16:483.
7 Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis
classiﬁcation criteria: an American College of Rheumatology/European
League Against Rheumatism collaborative initiative. Ann Rheum Dis
2010;69:1580–8.
8 Humphreys JH, Symmons DP. Postpublication validation of the 2010 American
College of Rheumatology/European League Against Rheumatism classiﬁcation
criteria for rheumatoid arthritis: where do we stand? Curr Opin Rheumatol
2013;25:157–63.
9 Jung SJ, Lee SW, Ha YJ, et al. Patients with early arthritis who fulﬁl the 1987 ACR
classiﬁcation criteria for rheumatoid arthritis but not the 2010 ACR/EULAR criteria.
Ann Rheum Dis 2012;71:1097–8.
10 Shi J, Knevel R, Suwannalai P, et al. Autoantibodies recognizing carbamylated
proteins are present in sera of patients with rheumatoid arthritis and predict joint
damage. Proc Natl Acad Sci USA 2011;108:17372–7.
11 Burska AN, Hunt L, Boissinot M, et al. Autoantibodies to posttranslational
modiﬁcations in rheumatoid arthritis. Mediators Inﬂamm 2014;2014:492873.
12 Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein (anti-CarP)
antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis
2014;73:780–3.
13 Gan RW, Trouw LA, Shi J, et al. Anti-carbamylated protein antibodies are present
prior to rheumatoid arthritis and are associated with its future diagnosis.
J Rheumatol 2015;42:572–9.
14 Brink M, Verheul MK, Ronnelid J, et al. Anti-carbamylated protein antibodies in the
pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple
anti-citrulline peptide antibodies and association with radiological damage. Arthritis
Res Ther 2015;17:536.
15 Shi J, van de Stadt LA, Levarht EW, et al. Anti-carbamylated protein antibodies are
present in arthralgia patients and predict the development of rheumatoid arthritis.
Arthritis Rheum 2013;65:911–15.
16 Symmons DP, Silman AJ. Aspects of early arthritis. What determines the evolution
of early undifferentiated arthritis and rheumatoid arthritis? An update from the
Norfolk Arthritis Register. Arthritis Res Ther 2006;8:214.
17 Department of Rheumatology UMCNN. DAS28. 2004. http://www.das-score.nl/
18 Wolfe F, Kleinheksel SM, Cathey MA, et al. The clinical value of the Stanford Health
Assessment Questionnaire Functional Disability Index in patients with rheumatoid
arthritis. J Rheumatol 1988;15:1480–8.
19 van der Linden MP, Knevel R, Huizinga TW, et al. Classiﬁcation of rheumatoid
arthritis: comparison of the 1987 American College of Rheumatology criteria and
the 2010 American College of Rheumatology/European League Against Rheumatism
criteria. Arthritis Rheum 2011;63:37–42.
20 Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to
clinical synovitis. Nat Rev Rheumatol 2012;8:573–86.
21 Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the
pre-clinical phase predicts progression to rheumatoid arthritis. PLoS ONE 2012;7:
e35296.
22 Nielen MM, Van SD, Reesink HW, et al. Speciﬁc autoantibodies precede the
symptoms of rheumatoid arthritis: a study of serial measurements in blood donors.
Arthritis Rheum 2004;50:380–6.
23 Hecht C, Englbrecht M, Rech J, et al. Additive effect of anti-citrullinated protein
antibodies and rheumatoid factor on bone erosions in patients with RA. Ann
Rheum Dis 2015;74:2151–6.
Humphreys JH, et al. Ann Rheum Dis 2016;75:1139–1144. doi:10.1136/annrheumdis-2015-207326 1143
Clinical and epidemiological research
group.bmj.com on May 31, 2016 - Published by http://ard.bmj.com/Downloaded from 
24 Yee A, Webb T, Seaman A, et al. Anti-CarP antibodies as promising marker to
measure joint damage and disease activity in patients with rheumatoid arthritis.
Immunol Res 2015;61:24–30.
25 Montes A, Perez-Pamoin E, Boveda MD, et al. Antibodies against carbamylated
proteins (anti-CarP), a new type of autoantibody, in Spanish patients with
rheumatoid arthritis. Ann Rheum Dis 2014;73(Suppl 2):129.
26 Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in
generic and disease-speciﬁc health-related quality of life questionnaires in clinical
trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478–87.
27 Pope JE, Khanna D, Norrie D, et al. The minimally important difference for the
health assessment questionnaire in rheumatoid arthritis clinical practice is smaller
than in randomized controlled trials. J Rheumatol 2009;36:254–9.
28 Wiles N, Symmons DP, Harrison B, et al. Estimating the incidence of
rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum
1999;42:1339–46.
29 Burgers LE, van Nies JA, Ho LY, et al. Long-term outcome of rheumatoid arthritis
deﬁned according to the 2010-classiﬁcation criteria. Ann Rheum Dis
2014;73:428–32.
1144 Humphreys JH, et al. Ann Rheum Dis 2016;75:1139–1144. doi:10.1136/annrheumdis-2015-207326
Clinical and epidemiological research
group.bmj.com on May 31, 2016 - Published by http://ard.bmj.com/Downloaded from 
Norfolk Arthritis Register
early inflammatory arthritis: results from the 
increased disease activity in patients with
associated with long-term disability and 
Anticarbamylated protein antibodies are
A Trouw and Suzanne MM Verstappen
LeendertMacGregor, Mark Lunt, Rene EM Toes, Deborah PM Symmons, 
Jennifer H Humphreys, Marije K Verheul, Anne Barton, Alexander J
doi: 10.1136/annrheumdis-2015-207326
6, 2015
2016 75: 1139-1144 originally published online OctoberAnn Rheum Dis 
 http://ard.bmj.com/content/75/6/1139
Updated information and services can be found at: 
These include:
Material
Supplementary
 26.DC1.html
http://ard.bmj.com/content/suppl/2015/10/06/annrheumdis-2015-2073
Supplementary material can be found at: 
References
 #BIBLhttp://ard.bmj.com/content/75/6/1139
This article cites 28 articles, 10 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (5062)Immunology (including allergy)
 (4878)Musculoskeletal syndromes
 (4572)Degenerative joint disease
 (539)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on May 31, 2016 - Published by http://ard.bmj.com/Downloaded from 
